Results 61 to 70 of about 564 (139)

VHHs as tools for therapeutic protein delivery to the central nervous system [PDF]

open access: yes, 2022
Background: The blood brain barrier (BBB) limits the therapeutic perspective for central nervous system (CNS) disorders. Previously we found an anti-mouse transferrin receptor (TfR) VHH (Nb62) that was able to deliver a biologically active neuropeptide ...
De Strooper, Bart   +5 more
core   +1 more source

Allosteric inhibition of Aurora-A kinase by a synthetic vNAR domain

open access: yes, 2016
The vast majority of clinically-approved protein kinase inhibitors target the ATP binding pocket directly. Consequently, many inhibitors have broad selectivity profiles and most have significant off-target effects.
Bayliss, R   +6 more
core   +1 more source

Oriented attachment of VNAR proteins, Q2 via site-selective modification, on PLGA–PEG nanoparticles enhances nanoconjugate performance [PDF]

open access: yes, 2019
This work was partially funded through a US-Ireland R&D Partnership grant (STL/5010/14, MRC grant MC_PC_15013). JCFN is funded by the EU’s Horizon 2020 programme under Marie-Curie grant agreement 675007.
Barelle, Caroline   +8 more
core   +5 more sources

Single domain antibody: Development and application in biotechnology and biopharma

open access: yesImmunological Reviews, Volume 328, Issue 1, Page 98-112, November 2024.
Summary Heavy‐chain antibodies (HCAbs) are a unique type of antibodies devoid of light chains, and comprised of two heavy chains‐only that recognize their cognate antigen by virtue of a single variable domain also referred to as VHH, single domain antibody (sdAb), or nanobody (Nb).
Ting Yu   +4 more
wiley   +1 more source

A fatal case of cerebral malaria complicated with Gemella bergeri bacteremia: role of Plasmodium mitochondrial cox3 gene and MALDI-TOF mass spectrometry for species identification [PDF]

open access: yes, 2022
Here, we described a fatal case of a 37-year-old returning traveller from Burkina Faso, West Africa, who presented with an acute fitting episode later diagnosed as cerebral malaria induced by Plasmodium falciparum based on microscopic examination and ...
Abdul Wahab, Asrul   +7 more
core   +2 more sources

Ueg Week 2020 Poster Presentations

open access: yes, 2020
United European Gastroenterology Journal, Volume 8, Issue S8, Page 144-887, October 2020.
wiley   +1 more source

Construction and next-generation sequencing analysis of a large phage-displayed VNAR single-domain antibody library from six naïve nurse sharks [PDF]

open access: yesAntibody Therapeutics, 2018
ABSTRACT Background Shark new antigen receptor variable domain (VNAR) antibodies can bind restricted epitopes that may be inaccessible to conventional antibodies. Methods Here, we developed a library construction method based on ...
Feng, Mingqian   +8 more
openaire   +2 more sources

Novel CD123 Binders for CAR-T Cell Therapy [PDF]

open access: yes, 2020
CD123- the a-chain of the IL-3 cytokine receptor (IL3RA)- is a promising new immunotherapeutic target due to its surface expression on a multitude of leukemic disorders and possible link to proliferative advantage.
Parekh, Farhaan
core  

Intracellular Antibodies for Drug Discovery and as Drugs of the Future. [PDF]

open access: yes, 2023
The application of antibodies in cells was first shown in the early 1990s, and subsequently, the field of intracellular antibodies has expanded to encompass antibody fragments and their use in target validation and as engineered molecules that can be ...
Rabbitts, TH
core   +2 more sources

In Vitro ELISA and Cell-Based Assays Confirm the Low Immunogenicity of VNAR Therapeutic Constructs in a Mouse Model of Human RA : An Encouraging Milestone to Further Clinical Drug Development [PDF]

open access: yes, 2020
Funding Information: The authors wish to acknowledge the funding support for this work from Scottish Enterprise (SE) (VNAR_001 (2012)), the Biotechnology and Biological Sciences Research Council (BBSRC) (BB/K010905/1), and Innovate UK (102865).Peer ...
Barelle, Caroline J   +2 more
core   +1 more source

Home - About - Disclaimer - Privacy